UNIVERSITY OF MINNESOTA

Trichoscopy enables clinicians to differentiate between scarring and non-scarring alopecia by identifying specific patterns such as scale adherence to hair fibers and loss of follicular ostia.

Acerand Therapeutics has dosed the first patient in a Phase I clinical trial of ACE-232, a novel oral CYP11A1 inhibitor for metastatic castration-resistant prostate cancer.

Mycovia Pharmaceuticals has enrolled the first participant in the PLATFORM-CM Phase 2 trial evaluating oteseconazole for cryptococcal meningitis treatment.

Eton Pharmaceuticals announced FDA approval of KHINDIVI (hydrocortisone) oral solution, marking the first and only FDA-approved liquid hydrocortisone formulation for pediatric patients aged 5 and older with adrenocortical insufficiency.

GT Biopharma has successfully completed dosing in the first cohort of its Phase 1 trial for GTB-3650, a second-generation TriKE immunotherapy, with no safety or tolerability issues observed.

A 35-year-old woman with stage 4 colon cancer achieved complete remission after receiving experimental CRISPR-Cas9 gene-edited immunotherapy at the University of Minnesota, marking an unprecedented outcome for advanced colorectal cancer.

University of Minnesota researchers conducted the first human trial using CRISPR/Cas9 to modify immune cells, demonstrating safety and potential effectiveness against advanced gastrointestinal cancers.

The American Heart Association has funded seven research projects with $1 million to identify which patients with obesity and cardiovascular disease benefit most from GLP-1/GIP medications.

• A new study published in Nature Communications Medicine reveals that 91.5% of tinnitus patients experienced clinically meaningful improvement after 12 weeks of treatment with the Lenire bimodal neuromodulation device. • The retrospective analysis of 220 patients represents one of the largest real-world studies of tinnitus treatment, confirming results from previous clinical trials that led to FDA approval in March 2023. • Lenire works by simultaneously delivering audio tones through headphones and mild electrical pulses to the tongue, offering a promising treatment option for the estimated 25 million Americans suffering from tinnitus.

The Trump administration has terminated 323 NIH grants worth $806 million focused on LGBTQ health research, affecting studies on HIV prevention, cancer, and mental health.